HemoBioTech, Inc (HMBT.OB) announced that the company’s Chairman & CEO, Dr. Arthur P. Bollon, will appear as one of the panelists on The McCuistion Program, airing Sunday, January 27, 2008 at 12:30PM. This program will be aired on the Dallas-Fort Worth KERA-Public Television, Channel 13.
The title of this program, “Blood Shortage Situation…The Challenges, Options & Solutions”, will utilize a panel of experts to give their input on the current blood shortage plague. Such experts include: Dr. Arthur Bollon. Chairman and CEO of HemoBioTech; Dr. Bernhard Mittemeyer, Former U.S. Army Surgeon General and HemoBioTech Director; and Dr. John Theus, Chief Medical Officer of South Central Division of the American Red Cross. The panel will discuss the current blood shortage situation and then provide potential solutions to this drastic problem.
HemoBioTech’s core product, HemoTech, can serve as an oxygen carrier and induces red blood cell production. It is discussed as a potential blood substitute to address the increasing demand for a safe and inexpensive human blood substitute product.
Dr. Bollon stated, “We are pleased to participate in The McCuistion Program on the important subject of blood availability and present HemoTech as a potential solution for the need for a viable substitute for human red blood cells.”
Let us hear your thoughts below: